Herceptin Proven To Benefit Women With HER2 Positive Early Breast Cancer Latest Results From The HERA Study

Study confirms Herceptin’s promise of extra years of living cancer free The Breast International Group (BIG) in collaboration with Roche announced that women with HER2 positive early breast cancer continue to benefit from Herceptin (trastuzumab) several years after treatment completion and as a result enjoy a longer life disease free. The patients were treated for […]

Pitt School Of Nursing To Sponsor Breast Cancer Conference

The University of Pittsburgh School of Nursing will host a free conference for women living with metastatic breast cancer. Adam Brufsky, M.D., Ph.D., co-director of the Magee Breast Cancer Program of UPMC Cancer Centers and medical director of the Women’s Cancer Center at Magee-Womens Hospital of UPMC, will discuss current and potential treatment options for […]

Addition Of Chemotherapy To Radiotherapy Continues To Increase Survival In Patients With Brain Tumours For Up To 5 Years, The Lancet

Giving patients with glioblastoma-the most common and aggressive form of primary brain tumour-the chemotherapy drug temozolomide in combination with radiotherapy increases their survival compared with those receiving radiotherapy alone and this improvement persists for up to 5 years, according to the final results of the EORTC-NCIC trial*, published Online first and in the May edition […]

European Commission And United States Food And Drug Administration (FDA) Both Approve New Options For Patients With Certain Primary Brain Tumors

Schering-Plough Corporation (NYSE: SGP) announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug. Temozolomide is marketed as TEMODAL(R) in the EU and as TEMODAR(R) in the US. The EU Commission Decision was based on the […]

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), announced positive safety and efficacy results from its Phase 2 monotherapy clinical study of ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this monotherapy study 66% of patients who received the highest dose achieved clinically meaningful disease stabilization according to RECIST criteria. No patient in any dose group exhibited […]

Lexicon Presents Clinical Data On LX1032 For Carcinoid Syndrome At European Neuroendocrine Tumor Society Meeting

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced that Dr. Philip Brown, senior vice president of clinical development at Lexicon, delivered an oral presentation at the annual meeting of the European Neuroendocrine Tumor Society (ENETS). The presentation summarized Phase 1 clinical trial results for […]

pSivida Corp: Enrollment Complete In BrachySil™ Dose Ranging Study

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PSI), a leading drug delivery company today announced the completion of enrollment of the BrachySil™ (P32 BioSilicon™) dose ranging clinical trial. Dr Paul Ashton, President and CEO of pSivida Corp. said, “We are very pleased to be progressing BrachySil™ as a potential new treatment for pancreatic cancer, a devastating disease for patients and […]

Younger Breast Cancer Patients Have Greater Chance Of Recurrence

Breast cancer patients 35 years old and younger have higher rates of their cancer returning after treatment than older women patients with the same stage of cancer, and their risk of recurrence is greatly impacted by the type of treatment they received, according to a March 1 study in the International Journal of Radiation Oncology […]

Breast-Specific Gamma Imaging (BSGI) Offers Greater Sensitivity Over Mammography, Ultrasound And MRI

Breast-Specific Gamma Imaging (BSGI) has been proven to be a highly sensitive imaging technique for the diagnosis of invasive lobular carcinoma (ILC) — a type of breast cancer that begins in the milk-producing glands (lobules) and then spreads to the surrounding breast tissues — according to a study published in the February 2009 issue of […]

Clinical Study Evaluates MORAb-009 Plus Standard Of Care For Extending Survival Of Patients With Mesothelioma

Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, has announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma. The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma. The primary objective of the study is […]